retatrutide phase 2 results weight loss Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, 2 trial conducted in the USA Retatrutide: What It Is &

"An increased pressure of the spinal fluid in the brain may be one of the mechanisms underlying migraine," Braca said

These setbacks demonstrate that while GLP-1 RAs show promising biomarker effects in the brain, translating them into meaningful clinical outcomes in neurodegeneration remains an unresolved challenge

There are currently 13 clinical trials investigating GLP-1RAs for PCOS registered with a National Clinical Trial number, targeting various outcomes of GLP-1RAs on PCOS patients, including weight loss, hormonal changes, metabolic health, and reproductive parameters

The glucagon receptor is especially interesting because it may influence energy expenditure and fuel metabolism